ANIX (Anixa Biosciences) Cyclically Adjusted PS Ratio: (As of Jul. 08, 2026)


ANIX Anixa Biosciences Inc ANIX
27 GF Score
Price $3.11
! 3 Warning Signs
View Full Analysis

What is Anixa Biosciences Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Anixa Biosciences  (NAS:ANIX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Anixa Biosciences Cyclically Adjusted PS Ratio Related Terms


Anixa Biosciences Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Anixa Biosciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anixa Biosciences Cyclically Adjusted PS Ratio Chart

Anixa Biosciences Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Anixa Biosciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ANIX vs BMEA, PMN, ATRA: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Anixa Biosciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anixa Biosciences Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's Cyclically Adjusted PS Ratio falls into.


ANIX
27GF Score
Anixa Biosciences Inc ANIX
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anixa Biosciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Anixa Biosciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Apr. 2026 is calculated as:

For example, Anixa Biosciences's adjusted Revenue per Share data for the three months ended in Apr. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Apr. 2026 (Change)*Current CPI (Apr. 2026)
=0/333.0200*333.0200
=0.000

Current CPI (Apr. 2026) = 333.0200.

Anixa Biosciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201607 0.011 240.628 0.015
201610 0.023 241.729 0.032
201701 0.000 242.839 0.000
201704 0.000 244.524 0.000
201707 0.025 244.786 0.034
201710 0.000 246.663 0.000
201801 0.000 247.867 0.000
201804 0.045 250.546 0.060
201807 0.020 252.006 0.026
201810 0.000 252.885 0.000
201901 0.000 251.712 0.000
201904 0.013 255.548 0.017
201907 0.000 256.571 0.000
201910 0.000 257.346 0.000
202001 0.000 257.971 0.000
202004 0.000 256.389 0.000
202007 0.000 259.101 0.000
202010 0.000 260.388 0.000
202101 0.020 261.582 0.025
202104 0.000 267.054 0.000
202107 0.000 273.003 0.000
202110 0.000 276.589 0.000
202201 0.000 281.148 0.000
202204 0.000 289.109 0.000
202207 0.000 296.276 0.000
202210 0.000 298.012 0.000
202301 0.000 299.170 0.000
202304 0.007 303.363 0.008
202307 0.000 305.691 0.000
202310 0.000 307.671 0.000
202401 0.000 308.417 0.000
202404 0.000 313.548 0.000
202407 0.000 314.540 0.000
202410 0.000 315.664 0.000
202501 0.000 317.671 0.000
202504 0.000 320.795 0.000
202507 0.000 323.048 0.000
202510 0.000 0.000
202601 0.000 325.252 0.000
202604 0.000 333.020 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Anixa Biosciences Business Description

Other Exchanges CY71:Germany
Address 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
27GF Score

Get the complete analysis for ANIX

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.11
Price